ZOLEDRONIC ACID - Z SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Beschikbaar vanaf:

SANDOZ CANADA INCORPORATED

ATC-code:

M05BA08

INN (Algemene Internationale Benaming):

ZOLEDRONIC ACID

Dosering:

4MG

farmaceutische vorm:

SOLUTION

Samenstelling:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

5ML

Prescription-type:

Prescription

Therapeutisch gebied:

BONE RESORPTION INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0141761002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2013-02-15

Productkenmerken

_Zoledronic Acid – Z _
_ _
_Page 1 of 51 _
PRODUCT MONOGRAPH
PR
ZOLEDRONIC ACID - Z
(Zoledronic acid for Injection)
4 mg zoledronic acid/5 mL incorporated as the monohydrate for
intravenous infusion
Bone Metabolism Regulator
Sandoz Canada Inc.
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
Date of Revision:
July 21, 2017
Control No. : 206684
_Zoledronic Acid – Z _
_ _
_Page 2 of 51 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT
INFORMATION....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
.............................................................................................................
12
DRUG INTERACTIONS
.............................................................................................................
20
DOSAGE AND ADMINISTRATION
.........................................................................................
20
OVERDOSAGE
............................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
25
STORAGE AND STABILITY
.....................................................................................................
29
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................... 29
PART II: SCIENTIFIC INFORMATION
...............................................................................
30
PHARMACEUTICAL INFORMATION
..................................................